Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.
Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.
复制标题
DOI:
10.1016/j.chembiol.2022.01.001
复制
发表时间:
2022-06-16
影响因子:
8.6
通讯作者:
Corson, Timothy W.
中科院分区:
文献类型:
--
作者:
Sishtla, Kamakshi;Lambert-Cheatham, Nathan;Lee, Bit;Han, Duk Hee;Park, Jaehui;Pasha, Sheik Pran Babu Sardar;Lee, Sanha;Kwon, Sangil;Muniyandi, Anbukkarasi;Park, Bomina;Odell, Noa;Waller, Sydney;Park, Il Yeong;Lee, Soo Jae;Seo, Seung-Yong;Corson, Timothy W.
Activity of the heme synthesis enzyme ferrochelatase (FECH) is implicated in multiple diseases. In particular, it is a mediator of neovascularization in the eye and thus an appealing therapeutic target for preventing blindness. However, no drug-like direct FECH inhibitors are known. Here, we set out to identify small molecule inhibitors of FECH as potential therapeutic leads using a high throughput screening approach to identify potent inhibitors of FECH activity. A structure-activity relationship study of a class of triazolopyrimidinone hits yielded drug-like FECH inhibitors. These compounds inhibit FECH in cells, bind the active site in cocrystal structures, and are anti-angiogenic in multiple in vitro assays. One of these promising compounds was anti-angiogenic in vivo in a mouse model of choroidal neovascularization. This foundational work may be the basis for new therapeutic agents to combat not only ocular neovascularization, but also other diseases characterized by FECH activity.
登录
查看更多内容
影响因子:
4.6
作者:
Chelakkot VS;Liu K;Yoshioka E;Saha S;Xu D;Licursi M;Dorward A;Hirasawa K
通讯作者:
Hirasawa K
影响因子:
9.7
作者:
Bhasin, G;Kausar, H;Athar, M
通讯作者:
Athar, M
影响因子:
3.3
作者:
El-Gendy, Mervat M. A.;Shaaban, Mohamed;Laatsch, Hartmut
通讯作者:
Laatsch, Hartmut
影响因子:
5.7
作者:
Inoue, Keiji;Fukuhara, Hideo;Shuin, Taro
通讯作者:
Shuin, Taro
影响因子:
4
作者:
Klaeger, Susan;Gohlke, Bjoern;Kuster, Bernhard
通讯作者:
Kuster, Bernhard